How I treat the older patient with acute myeloid leukemia

G Ossenkoppele, Bob Löwenberg

Research output: Contribution to journalArticleAcademicpeer-review

161 Citations (Scopus)


Acute myeloid leukemia (AML) in older patients presents a notable therapeutic challenge to the clinical hematologist. The clinical biology of AML among patients is highly heterogeneous. Interpatient variations are relevant for prognosis and treatment choice. Outcome of treatment for patients of advanced age is often compromised by comorbid conditions and an enhanced susceptibility to toxicities from therapy. Here we present selected clinical vignettes that highlight distinct representative situations derived from clinical practice. The vignettes are specifically discussed in light of the perspective of treating older patients with leukemia. We review the clinical significance of various cytogenetic and molecular features of the disease, and we examine the various currently available treatment options as well as the emerging prognostic algorithms that may offer guidance in regard to personalized therapy recommendations. The dilemmas in tailoring treatment selection in this category of patients with AML are the central theme in this discussion.
Original languageUndefined/Unknown
Pages (from-to)767-774
Number of pages8
Issue number5
Publication statusPublished - 2015

Research programs

  • EMC MM-02-41-03

Cite this